Atomoxetine Versus Placebo in Children With Attention Deficit/Hyperactivity Disorder (ADHD)
Phase 2
Completed
- Conditions
- Attention Deficit Hyperactivity Disorder
- Registration Number
- NCT00191295
- Lead Sponsor
- Eli Lilly and Company
- Brief Summary
Atomoxetine versus placebo in Children with Attention-Deficit/Hyperactivity Disorder (ADHD)
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 240
Inclusion Criteria
- Patients are diagnosed with ADHD
- Patients must be able to swallow capsules
- Patients must be of normal intelligence
Exclusion Criteria
- Patients who weigh less than 15 kg or more than 75 kg
- Patients with organic brain disease (for example, dementia or traumatic brain injury residual)
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Change of total score on ADHD RS-IV-JParent Version: Investigation-Administered and Scored
- Secondary Outcome Measures
Name Time Method Relationship between atomoxetine doses and both efficacy and safety variables Plasma concentration of atomoxetine and its metabolites Changes on ADHD RS-IV-J-School Version score
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie Atomoxetine's efficacy in modulating norepinephrine reuptake for ADHD treatment?
How does Atomoxetine's safety profile compare to stimulant medications like methylphenidate in pediatric ADHD populations?
Which biomarkers correlate with treatment response to Atomoxetine in children with ADHD subtypes (e.g., combined, inattentive)?
What are the long-term cardiovascular risks of Atomoxetine in ADHD patients, and how are they managed clinically?
How does Atomoxetine's pharmacokinetics differ from other SNRIs in pediatric ADHD trials sponsored by Eli Lilly?
Trial Locations
- Locations (1)
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician
🇯🇵Wakayama, Japan
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician🇯🇵Wakayama, Japan